Immuneering Goodwill and Intangible Assets 2021-2024 | IMRX

Immuneering goodwill and intangible assets from 2021 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Immuneering Goodwill and Intangible Assets 2021-2024 | IMRX

Immuneering goodwill and intangible assets from 2021 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$146.3B
Gilead Sciences (GILD)$114.5B
Bristol Myers Squibb (BMY)$114.2B
Vertex Pharmaceuticals (VRTX)$108.7B
CSL (CSLLY)$83.4B
Regeneron Pharmaceuticals (REGN)$74.9B
GSK (GSK)$69.3B
Argenex SE (ARGX)$38.7B
Alnylam Pharmaceuticals (ALNY)$31.8B
BioNTech SE (BNTX)$26.8B
Illumina (ILMN)$21.7B
BeiGene (ONC)$20.5B
Biogen (BIIB)$20.5B
Incyte (INCY)$13.9B
Genmab (GMAB)$13.8B
Genmab (GNMSF)$13.7B
Intra-Cellular Therapies (ITCI)$13.4B
Moderna (MRNA)$13.1B
Insmed (INSM)$13B
Bio-Techne Corp (TECH)$12B
BioMarin Pharmaceutical (BMRN)$11.7B
Sarepta Therapeutics (SRPT)$11.3B
Vaxcyte (PCVX)$10.6B
QIAGEN (QGEN)$10.5B
Exelixis (EXEL)$10.3B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Exact Sciences (EXAS)$9.6B
Bio-Rad Laboratories (BIO.B)$9.5B
Repligen (RGEN)$9B
Roivant Sciences (ROIV)$8.1B